Original Research
The study found that coronary cannulation after TAVI with the Evolut FX valve was highly feasible due to a high rate of commissural and coronary alignment, but coronary misalignment was the strongest predictor of suboptimal coronary cannulation for both the left and right coronary arteries.
letter to the editor
This letter discusses the need to evaluate the addition of novel pharmacotherapy to current regimens in order to improve outcomes related to leaflet thrombosis and cerebral injury after TAVI procedures.
letter to the editor
The reply adresses the need for further research on optimal post-TAVI regimens to balance ischaemic, embolic, bleeding, and cognitive risks, and the prevention of covert brain injury in the TAVI population.
Editorial
Expert Consensus
This scientific statement provides guidance on the management of patients with cardiac implantable electronic device leads crossing the tricuspid valve who are undergoing transcatheter tricuspid valve interventions.
.jpg)
Viewpoint
Original Research
Flashlight
The key findings from the 5-year follow-up of transcatheter tricuspid valve replacement with the EVOQUE valve include normal leaflet function, minimal residual tricuspid regurgitation, no heart failure hospitalizations, and significant improvement in the patient's symptoms.
Original Research
Editorial
Original Research
State-of-the-Art
Simultaneous Publication
The key findings from this 5-year study of the early-generation Intrepid transapical transcatheter mitral valve replacement system were sustained mitral regurgitation reduction, durable hemodynamic valve performance, and improved functional status among survivors, despite high mortality rates.
Simultaneous Publication
This study found that the novel DurAVR transcatheter heart valve demonstrated promising 30-day clinical and echocardiographic outcomes, including a low rate of prosthesis-patient mismatch, in patients with small aortic annuli.
